Uncategorized

Medtronic deal could result in $80M windfall for Covidien executive team

             
Managing Editor, Online & Research-Boston Business Journal
Email  |  Twitter

Covidien plc’s shareholders aren’t the only people who stand to make a hefty profit if the company is sold as planned for $43 billion to Medtronic: Financial filings also indicate that the local medical device maker’s senior executive team is in line for a windfall if they part from the newly merged company once the deal is done.

According to recent filings with the Securities and Exchange Commission, Covidien’s top-five executives stand to reap approximately $80 million in cash and equity payments if the they are terminated from the company after a change in control. The potential payouts would include accelerated salaries, bonuses and vested equity awards that average out to approximately $16 million per executive.

The same group of senior executives, led by CEO Jose Almeida, received total compensation of approximately $24 million in fiscal 2013 and realized another $30 million in value from vested option and restricted stock awards from prior years. That compensation as well as the team’s change-in-control payouts do not include tens-of-millions more in Mansfield-based Covidien shares already owned, which in the case of Almeida alone were worth approximately $73 million based on Monday’s stock close of around $87 a share.

The Covidien team’s potential severance packages, should each member leave the company following a change in control, are as follows:

  • CEO José E. Almeida $37.3 million, including $7.4 million in cash severance; $1.6 million in accelerated bonuses; $8.5 million in accelerated vesting of option awards; $19.7 million in accelerated vesting of stock awards and $83,535 in welfare benefits and outplacement services.
  • CFO Charles J. Dockendorff: $15.1 million, including $3.2 million in cash severance; $675,000 in accelerated bonuses; $4 million in accelerated vesting of option awards; $7 million in accelerated vesting of stock awards and $71,162 in welfare benefits; and outplacement services.
  • Medical Device Group President Bryan C. Hanson : $10.5 million, including $2.1 million in cash severance; $585,000 in accelerated bonuses; $2.2 million in accelerated vesting of option awards; $5.5 million in accelerated vesting of stock awards and $71,162 in welfare benefits; and outplacement services.
  • Developed Markets Group President Peter L. Wehrly: $9.3 million, including $2.1 million in cash severance; $426,000 in accelerated bonuses; $1.8 million in option awards; $4.9 million in stock awards and $71,162 in welfare benefits; and outplacement services.
  • General Counsel John H. Masterson: $7.7 million, including $2.3 million in cash severance; $472,000 in accelerated bonuses; $1.8 million in accelerated vesting of option awards; $3.1 million in accelerated vesting of stock awards; and $71,162 in welfare benefits and outplacement services.

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button